Skip to content

Effect of Intranasal Dexmedetomidine Combined with Intravenous Lidocaine Infusion on Emergence Agitation and Postoperative Sleep Quality in Children

Effect of Intranasal Dexmedetomidine Combined with Intravenous Lidocaine Infusion on Emergence Agitation and Postoperative Sleep Quality in Children

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400094855
Enrollment
Unknown
Registered
2024-12-30
Start date
2024-12-31
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Tonsillitis,Adenoid Hypertrophy

Interventions

Dexmedetomidine intranasal administration group (D group).:Thirty minutes before surgery, the child is placed in a sitting position, the nasal cavity is cleaned, the spray nozzle is inserted into the
Lidocaine pump infusion group (L group):Thirty minutes before surgery, the child is seated and both nostrils are cleaned with saline spray. During anesthesia induction, 1.5mg/kg lidocaine (based on id
Dexmedetomidine intranasal administration combined with lidocaine pump infusion group (DL group):Thirty minutes before surgery, the child is placed in a sitting position. After cleaning the nasal cavi

Sponsors

First Affiliated Hospital of Gannan Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
2 Years to 12 Years

Inclusion criteria

Inclusion criteria: (1) ASA classification of grade I–II; (2) Children aged 2–12 years undergoing elective tonsillectomy and adenoidectomy in our hospital; (3) Body weight ranging from 19.4 to 28.0 kg; (4) Agree to participate in the study

Exclusion criteria

Exclusion criteria: (1) Abnormal liver or kidney function, history of heart disease, asthma, or central nervous system disorders; (2) Allergy to the study drugs; (3) History of anxiety, depression, or other psychiatric disorders, or sleep disturbances; (4) Behavioral and developmental disorders (e.g., attention deficit hyperactivity disorder or learning disabilities); (5) Severe cardiac conduction block (including sinoatrial, atrioventricular, or intraventricular block); (6) Wolff-Parkinson-White syndrome; (7) Structural abnormalities of the nasal cavity; (8) Use of other psychotropic drugs before surgery.

Design outcomes

Primary

MeasureTime frame
incidence of emergence agitation;

Secondary

MeasureTime frame
perioperative sleep quality;postoperative pain scores ;vital signs;extubation time;incidence of delayed awakening;incidence of adverse events;PACU length of stay;surgery duration;intraoperative propofol and remifentanil dosages;intraoperative blood loss;

Countries

China

Contacts

Public ContactLifang Zhan

First Affiliated Hospital of Gannan Medical University

zhanlifangzouping@163.com+86 158 7973 1530

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026